EP3919052A1 — Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
Assigned to Yamada Ken-Ichi · Expires 2021-12-08 · 4y expired
What this patent protects
The present invention provides a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatmen…
USPTO Abstract
The present invention provides a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatment, the composition comprising an effective amount of one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method threfor, a group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine and indapamide.
Drugs covered by this patent
- Evrysdi (RISDIPLAM) · Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.